Point-of-Care Growth Leverage Novel Dx's portable, battery-powered, sample-to-answer molecular diagnostic platform to target rapid testing in point-of-care settings such as urgent care clinics, community hospitals, EMS, and mobile clinics. The ability to deliver accurate results within minutes can drive on-site testing, faster treatment decisions, and higher patient throughput, creating opportunities for direct sales of instruments, consumables, and service agreements.

Regulated Quality Advantage ISO 13485 certification and a regulated quality framework position Novel Microdevices as a trusted supplier for hospitals, clinics, and government contracts. Emphasize traceability, quality control, and audit readiness to win procurement deals with healthcare networks, payers, and public health programs. This quality footing can reduce sales cycle friction and help with multi-site deployments.

Public Health Partnerships Funding from NIH RADx Tech and CARB-X initiatives signals potential for public sector pilots and collaborations. Target opportunities include outbreak response projects and rapid STI diagnostics, where funders may support platform adoption in underserved or high-need communities.

OEM and Collaborations OEM and strategic partnerships could accelerate market reach. The platform’s rapid molecular testing and portable form factor make it attractive for larger medtech players seeking to augment their point-of-care lines or to co-develop integrated solutions, enabling joint go-to-market, manufacturing scale, and broader distribution.

Funding Momentum Signals Sustained investor momentum and milestone-driven funding indicate growth in production capability and a broader sales footprint. Leverage this trajectory to secure early pilots with regional health systems, hospitals, and urgent care networks, and to demonstrate ROI through faster diagnostics and improved patient outcomes.